BACKGROUND: The prevalence of obesity continues to increase worldwide. Because obesity is associated with a number health-related problems as well as a shortened life span, treating obesity is an important clinical concern. Although various treatments are currently available, many are not efficacious in the long term. Therefore, additional medical treatment options for morbidly obese individuals must be explored. In this study, we examined the effects of the intragastric balloon MedSil on anthropometric measures and hormones associated with lipid and energy metabolism. METHODS: Twenty-two obese patients underwent insertion of the intragastric balloon MedSil following a clinical exam, body composition scan, and collection of blood samples. Six months following implantation of the balloon, additional anthropometric and serological measures were taken. RESULTS: Six months following insertion of the MedSil balloon, we observed significant decreases in body weight, body mass index, and fat mass. Compared with baseline levels, ghrelin serum levels were increased significantly, while leptin, FGF21, and glycated hemoglobin levels significantly decreased, 6 months after balloon insertion. CONCLUSIONS: The MedSil intragastric balloon is a safe and effective treatment for morbid obesity, with positive effects on anthropometric measures and lipid metabolism.

Department of Physiology and Pathophysiology Faculty of Medicine University of Ostrava Syllabova 19 Ostrava 703 00 Czech Republic

Zobrazit více v PubMed

Obesity and overweight, Factsheet N°311, 2011March [cited 2013 Jul 30]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html.

Ackroyd R, Mouiel J, Chevallier JM, et al. Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes Surg. 2006;16(11):1488–1503. doi: 10.1381/096089206778870067. PubMed DOI

Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755–1767. doi: 10.1016/j.jada.2007.07.017. PubMed DOI

Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17(4):317–335. doi: 10.1111/j.1365-277X.2004.00531.x. PubMed DOI

Konopko-Zubrzycka M, Baniukiewicz A, Wróblewski E, et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab. 2009;94(5):1644–1649. doi: 10.1210/jc.2008-1083. PubMed DOI

Pinheiro J, Bates D, DebRoy S, et al. (2013). nlme: Linear and nonlinear mixed effects models. R package version 3.1–109.

R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.

Genco A, Cipriano M, Bacci V, et al. BioEnterics intragastric balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 2006;30(1):129–133. doi: 10.1038/sj.ijo.0803094. PubMed DOI

McFarland RJ, Grundy A, Gazet JC, et al. The intragastric balloon: a novel idea proved ineffective. Br J Surg. 1987;74(2):137–139. doi: 10.1002/bjs.1800740222. PubMed DOI

Giardiello C, Borrelli A, Silvestri E, et al. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg. 2012;22(12):1916–1919. doi: 10.1007/s11695-012-0786-x. PubMed DOI

Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008;18(8):989–992. doi: 10.1007/s11695-007-9383-9. PubMed DOI

Imaz I, Martínez-Cervell C, García-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–846. doi: 10.1007/s11695-007-9331-8. PubMed DOI

Dumonceau JM. Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–1617. doi: 10.1007/s11695-008-9593-9. PubMed DOI

Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–1088. doi: 10.1007/s11695-009-9879-6. PubMed DOI

Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14(7):991–998. doi: 10.1381/0960892041719671. PubMed DOI

Evans D, Scott MH. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg. 2001;88(9):1245–1248. doi: 10.1046/j.0007-1323.2001.01840.x. PubMed DOI

Lecumberri E, Krekshi W, Matía P, et al. Effectiveness and safety of air-filled balloon Heliosphere BAG® in 82 consecutive obese patients. Obes Surg. 2011;21(10):1508–1512. doi: 10.1007/s11695-010-0314-9. PubMed DOI

Dogan UB, Gumurdulu Y, Akin MS, et al. Five percent weight lost in the first month of intragastric balloon treatment may be a predictor for long-term weight maintenance. Obes Surg. 2013;23(7):892–896. doi: 10.1007/s11695-013-0876-4. PubMed DOI

Danielsen KK, Svendsen M, Mæhlum S, et al. Changes in body composition, cardiovascular disease risk factors, and eating behavior after an intensive lifestyle intervention with high volume of physical activity in severely obese subjects: a prospective clinical controlled trial. J Obes. 2013. doi: 10.1155/2013/325464. Epub 2013 Apr 22. PMID: 23710347; PMCID: PMC3654355. PubMed PMC

Weck M, Bornstein SR, Barthel A, et al. Strategies for successful weight reduction—focus on energy balance. Dtsch Med Wochenschr. 2012;137(43):2223–2228. doi: 10.1055/s-0032-1327232. PubMed DOI

Wycherley TP, Brinkworth GD, Clifton PM, et al. Comparison of the effects of 52 weeks weight loss with either a high-protein or high-carbohydrate diet on body composition and cardiometabolic risk factors in overweight and obese males. Nutr Diabetes. 2012;2:e40. doi: 10.1038/nutd.2012.11. PubMed DOI PMC

Sekino Y, Imajo K, Sakai E, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med. 2011;50(21):2449–2455. doi: 10.2169/internalmedicine.50.5672. PubMed DOI

Mathus-Vliegen EM, Eichenberger RI. Fasting and Meal-Suppressed Ghrelin Levels Before and After Intragastric Balloons and Balloon-Induced Weight Loss. Obes Surg. 2013 Aug 6. [Epub ahead of print] PMID: 23918282. PubMed

Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649. doi: 10.1007/s11695-007-9109-z. PubMed DOI

Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007;8(1):21–34. doi: 10.1111/j.1467-789X.2006.00270.x. PubMed DOI

Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol. 2003;24(4):225–253. doi: 10.1016/j.yfrne.2003.10.001. PubMed DOI

Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. doi: 10.1038/45230. PubMed DOI

Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714–1719. doi: 10.2337/diabetes.50.8.1714. PubMed DOI

Nikolic M, Boban M, Ljubicic N, et al. Morbidly obese are ghrelin and leptin hyporesponders with lesser intragastric balloon treatment efficiency : ghrelin and leptin changes in relation to obesity treatment. Obes Surg. 2011;21(10):1597–1604. doi: 10.1007/s11695-011-0414-1. PubMed DOI

Roubos EW, Dahmen M, Kozicz T, et al. Leptin and the hypothalamo-pituitary-adrenal stress axis. Gen Comp Endocrino. 2012;177(1):28–36. doi: 10.1016/j.ygcen.2012.01.009. PubMed DOI

Belgardt BF, Brüning JC. CNS leptin and insulin action in the control of energy homeostasis. Ann N Y Acad Sci. 2010 Nov;1212:97–113. doi: 10.1111/j.1749-6632.2010.05799.x. Epub 2010 Nov 11. Review. PMID: 21070248. PubMed

Mion F, Gincul R, Roman S, et al. Tolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter study. Obes Surg. 2007;17(6):764. doi: 10.1007/s11695-007-9141-z. PubMed DOI

Iglesias P, Selgas R, Romero S, et al. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol. 2012;167(3):301–309. doi: 10.1530/EJE-12-0357. PubMed DOI

Reinehr T, Woelfle J, Wunsch R, et al. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab. 2012;97(6):2143–2150. doi: 10.1210/jc.2012-1221. PubMed DOI

Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246–1253. doi: 10.2337/db07-1476. PubMed DOI

Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009;71(3):369–375. doi: 10.1111/j.1365-2265.2008.03502.x. PubMed DOI

Mai K, Schwarz F, Bobbert T, et al. Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism. 2011;60(2):306–311. doi: 10.1016/j.metabol.2010.02.016. PubMed DOI

Woelnerhanssen B, Peterli R, Steinert RE, et al. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. Surg Obes Relat Dis. 2011;7(5):561–568. doi: 10.1016/j.soard.2011.01.044. PubMed DOI

Haluzíková D, Lacinová Z, Kaválková P, et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring) 2013;21(7):1335–1342. doi: 10.1002/oby.20208. PubMed DOI

Dastis SN, François E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41(7):575–580. doi: 10.1055/s-0029-1214826. PubMed DOI

Short-term outcomes of the new intragastric balloon End-Ball® for treatment of obesity

Elipse™, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study

Laparoscopic gastric plication and its effect on saccharide and lipid metabolism: a 12-month prospective study